The Exposure of Breast Cancer Cells to Fulvestrant and Tamoxifen Modulates Cell Migration Differently
Open Access
- 2 July 2013
- journal article
- research article
- Published by Hindawi Limited in BioMed Research International
- Vol. 2013, 1-14
Abstract
There is no doubt that there are increased benefits of hormonal therapy to breast cancer patients; however, current evidence suggests that estrogen receptor (ER) blockage using antiestrogens is associated with a small induction of invasivenessin vitro. The mechanism by which epithelial tumor cells escape from the primary tumor and colonize to a distant site is not entirely understood. This study investigates the effect of two selective antagonists of the ER, Fulvestrant (Fulv) and Tamoxifen (Tam), on the invasive ability of breast cancer cells. We found that 17β-estradiol (E2) demonstrated a protective role regarding cell migration and invasion. Fulv did not alter this effect while Tam stimulated active cell migration according to an increase in Snail and a decrease in E-cadherin protein expression. Furthermore, both tested agents increased expression of matrix metalloproteinases (MMPs) and enhanced invasive potential of breast cancer cells. These changes were in line with focal adhesion kinase (FAK) rearrangement. Our data indicate that the anti-estrogens counteracted the protective role of E2concerning migration and invasion since their effect was not limited to antiproliferative events. Although Fulv caused a less aggressive result compared to Tam, the benefits of hormonal therapy concerning invasion and metastasis yet remain to be investigated.Keywords
Funding Information
- EOGE Oncological Research Fund
This publication has 50 references indexed in Scilit:
- Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1Breast Cancer Research, 2011
- How Do Cells Make Decisions: Engineering Micro- and Nanoenvironments for Cell MigrationJournal of Oncology, 2010
- Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 2010
- Interstitial cell migration: integrin-dependent and alternative adhesion mechanismsCell and tissue research, 2009
- Epithelial-Mesenchymal Transitions in Development and DiseaseCell, 2009
- Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The ‘personalised’ approach?European Journal of Cancer, 2009
- The role of epithelial-mesenchymal transition in cancer pathologyPathology, 2007
- MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cellsBreast Cancer Research and Treatment, 2006
- Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancerEndocrine-Related Cancer, 2005
- E-cadherin expression in primary carcinomas of the breast and its distant metastasesBreast Cancer Research, 2003